Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 8/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627994 | 0.81 | SLC22A12 (0.49) | CA12CA1CA2CA9IKBKB | |
| SCHEMBL6857747 | 0.80 | PGR (0.52) | GRM4PGRSLC22A12NR3C1NR3C2 | |
| SCHEMBL13065706 | 0.79 | SLC22A12 (0.43) | IKBKBCHUKPGRSLC22A12NR3C1 | |
| SCHEMBL13365322 | 0.78 | BRPF1 (0.42) | GRM4SLC22A12 | |
| SCHEMBL6863684 | 0.78 | ALDH1A1 (0.60) | PGRSLC22A12NR3C1NR3C2AR | |
| SCHEMBL2678340 | 0.77 | SLC22A12 (0.62) | PGRSLC22A12NR3C1NR3C2AR | |
| SCHEMBL2034092 | 0.75 | LMNA (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL526634 | 0.74 | HPGD (0.54) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL1542615 | 0.74 | ADRA2C (0.49) | CA12CA1CA2CA9PGR | |
| SCHEMBL849569 | 0.73 | ALDH1A1 (0.63) | GRM4CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | GRM4 4577/4885CA12 4866/4885CA1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.